RxDoctor Payments Data

Poonam Duggal, MD

Family Medicine · Stockton, CANPI 1356386510

Payments from drug & device makers

$3,828in general payments, 2019–2025

Across 132 payments — averaging $29.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$785
  • Pfizer$478
  • Novo Nordisk$401
  • Lilly USA, LLC$359
  • Corcept Therapeutics$275
  • GSK$273
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,823100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,828 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$113,747
Medicare patients
137
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$67,852
OzempicSemaglutide50$61,859
JanuviaSitagliptin Phosphate28$30,432
XareltoRivaroxaban32$25,285
EliquisApixaban23$20,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,527
EntrestoSacubitril/Valsartan14$14,975
MyrbetriqMirabegron14$13,257
TradjentaLinagliptin16$11,595
Atorvastatin Calcium729$8,410
JanumetSitagliptin Phos/Metformin Hcl14$7,459
Albuterol Sulfate HfaAlbuterol Sulfate196$7,316
Rosuvastatin Calcium278$6,120
Losartan Potassium462$5,865
Levothyroxine Sodium331$5,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$132$79,44671 claims
Novo NordiskOzempic$401$61,85950 claims
GSKTrelegy Ellipta, Arnuity Ellipta$273$22,29144 claims
PfizerEliquis, Paxlovid$478$22,12458 claims
NovartisEntresto$15$14,97514 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$29$4,81419 claims
AstraZenecaSymbicort$785$3,63611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →